Clinical Trials Logo

Filter by:
NCT ID: NCT01609296 Completed - Clinical trials for Peripheral Arterial Disease

IN.PACT Global Clinical Study

Start date: May 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiralâ„¢ Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries in a "real world" patient population.

NCT ID: NCT01609140 Completed - Clinical trials for Coronary Heart Disease

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Start date: May 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c levels well above goal.

NCT ID: NCT01606995 Completed - Atrial Fibrillation Clinical Trials

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

XANTUS
Start date: June 12, 2012
Phase:
Study type: Observational

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

NCT ID: NCT01604278 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

GLOW6
Start date: May 2012
Phase: Phase 3
Study type: Interventional

This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.

NCT ID: NCT01603641 Completed - Cerebral Palsy Clinical Trials

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

Start date: November 5, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.

NCT ID: NCT01603628 Completed - Cerebral Palsy Clinical Trials

BOTOX® Treatment in Pediatric Lower Limb Spasticity

Start date: September 11, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.

NCT ID: NCT01603615 Completed - Stroke Clinical Trials

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Start date: October 30, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.

NCT ID: NCT01603602 Completed - Stroke Clinical Trials

BOTOX® Treatment in Pediatric Upper Limb Spasticity

Start date: July 12, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.

NCT ID: NCT01599650 Completed - Clinical trials for Branch Retinal Vein Occlusion

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

BRIGHTER
Start date: May 2012
Phase: Phase 3
Study type: Interventional

This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.

NCT ID: NCT01598987 Completed - Liver Transplant Clinical Trials

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This study is designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.